Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

158.99USD
4:00pm EDT
Price Change (% chg)

$-4.69 (-2.87%)
Prev Close
$163.68
Open
$161.03
Day's High
$163.31
Day's Low
$158.47
Volume
560,764
Avg. Vol
459,199
52-wk High
$185.06
52-wk Low
$102.33

ALXN.OQ

Chart for ALXN.OQ

About

Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with... (more)

Overall

Beta: 0.64
Market Cap (Mil.): $32,378.36
Shares Outstanding (Mil.): 197.82
Dividend: --
Yield (%): --

Financials

  ALXN.OQ Industry Sector
P/E (TTM): 82.26 35.82 36.29
EPS (TTM): 1.99 -- --
ROI: 14.19 18.85 18.13
ROE: 15.73 19.57 18.95
Search Stocks

Alexion Pharma recalls certain lots of intravenous drug Soliris

- Alexion Pharmaceuticals Inc said it is voluntarily recalling certain lots of Soliris, an intravenous drug for two potentially fatal blood disorders that can damage the kidneys, heart and brain.

02 Jun 2014

Alexion Pharma recalls certain lots of intravenous drug Soliris

June 2 - Alexion Pharmaceuticals Inc said it is voluntarily recalling certain lots of Soliris, an intravenous drug for two potentially fatal blood disorders that can damage the kidneys, heart and brain.

02 Jun 2014

UPDATE 1-Alexion Pharma raises 2014 profit forecast again

* 1st-quarter adj earnings $1.53/share vs est $1.26 (Adds details, analyst comment)

24 Apr 2014

Alexion Pharma raises 2014 profit forecast on strong Soliris sales

April 24 - Alexion Pharmaceuticals Inc reported stronger-than-expected adjusted net earnings due to robust sales of its sole product on the market, Soliris, and it raised its full-year profit forecast for the second time in less than two months.

24 Apr 2014

Alexion raises forecast as France boosts Soliris reimbursement

- Alexion Pharmaceuticals Inc raised its profit and sales forecast for the year after the French government agreed to raise reimbursement payments for the company's treatment for two rare blood disorders.

10 Mar 2014

UPDATE 2-Alexion raises forecast as France boosts Soliris reimbursement

* Decision should help reimbursement talks in Spain, Italy-analyst

10 Mar 2014

Alexion to book additional Soliris sales, raises outlook

March 10 - Alexion Pharmaceuticals Inc revised its profit and sales outlook for the year after the French government agreed to raise reimbursement payments for the company's lead drug, Soliris.

10 Mar 2014

British watchdog wants U.S. biotech Alexion to justify cost of drug

LONDON, March 4 - Britain's healthcare costs watchdog has asked U.S. biotech group Alexion Pharmaceuticals to explain the high price for its Soliris drug before deciding whether the treatment should be paid for by the state health service.

03 Mar 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $100.09 -2.21
Abbott Laboratories (ABT.N) $42.12 -0.74
Sanofi SA (SASY.PA) €78.62 +1.73
Bristol-Myers Squibb Co (BMY.N) $50.62 -0.50
Bristol-Myers Squibb Co (BMYMP.PK) $860.00 -63.10
Amgen, Inc. (AMGN.OQ) $127.39 -2.62

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks